OTS167 Inhibits FLT3 Expression in FLT3 Mutant Acute Myeloid Leukemia

被引：0
|
作者：
Eisfelder, Bartholomew [1 ]
Wynne, Joseph [1 ]
Colton, Margert [1 ]
Cheng, Jason [2 ]
Odenike, Olatoyosi [1 ]
Alachkar, Houda [3 ]
Stock, Wendy [1 ]
机构：
[1] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, Hematopathol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA
[3] Univ Southern Calif, Sch Pharm, Dept Clin Pharm & Pharmaceut Econ & Policy, Los Angeles, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷
关键词：
FLT3; FLT3-ITD; MELK; OTS167; eIF4B; AML; acute myeloid leukemia;
D O I：
10.1016/j.clml.2019.07.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-388
引用
收藏
页码：S239 / S240
页数：2
相关论文
共 50 条
  • [41] Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3/ITD Acute Myeloid Leukemia
    Tarlock, Katherine
    Thurman, Robert
    Rohm, Rory
    Biechele, Travis
    Arthur, Bill
    Meshinchi, Soheil
    BLOOD, 2018, 132
  • [42] SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
    Puissant, Alexandre
    Fenouille, Nina
    Alexe, Gabriela
    Pikman, Yana
    Bassi, Christopher F.
    Mehta, Swapnil
    Du, Jinyan
    Kazi, Julhash U.
    Luciano, Frederic
    Ronnstrand, Lars
    Kung, Andrew L.
    Aster, Jon C.
    Galinsky, Ilene
    Stone, Richard M.
    DeAngelo, Daniel J.
    Hemann, Michael T.
    Stegmaier, Kimberly
    CANCER CELL, 2014, 25 (02) : 226 - 242
  • [43] Safety of FLT3 inhibitors in patients with acute myeloid leukemia
    Cerchione, Claudio
    Peleteiro Raindo, Andres
    Mosquera Orgueira, Adrian
    Mosquera Torre, Alicia
    Bao Perez, Laura
    Marconi, Giovanni
    Isidori, Alessandro
    Perez Encinas, Manuel Mateo
    Martinelli, Giovanni
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 851 - 865
  • [44] Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation
    Carlos Best-Aguilera
    O. Rodrigo Gómez-Vázquez
    A. Elizabeth Guzmán-Hernández
    R. Monserrat Rojas-Sotelo
    Current Oncology Reports, 2017, 19
  • [45] FLT3 inhibition as a targeted therapy for acute myeloid leukemia
    Sanz, Miguel
    Burnett, Alan
    Lo-Coco, Francesco
    Lowenberg, Bob
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (06) : 594 - 600
  • [46] Clinical use of FLT3 inhibitors in acute myeloid leukemia
    Sutamtewagul, Grerk
    Vigil, Carlos E.
    ONCOTARGETS AND THERAPY, 2018, 11 : 7041 - 7052
  • [47] Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia The Case for Total Therapy
    Perl, Alexander E.
    Pratz, Keith W.
    CANCER JOURNAL, 2022, 28 (01): : 14 - 20
  • [48] The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
    Chang, E.
    Ganguly, S.
    Rajkhowa, T.
    Gocke, C. D.
    Levis, M.
    Konig, H.
    LEUKEMIA, 2016, 30 (05) : 1025 - 1032
  • [49] FLT3 inhibition as tailored therapy for acute myeloid leukemia
    Martinelli, G
    Piccaluga, PP
    Lo Coco, F
    HAEMATOLOGICA, 2003, 88 (01) : 4 - 7
  • [50] Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia
    Levis, Mark
    FUTURE ONCOLOGY, 2014, 10 (09) : 1571 - 1579
12345